There is currently no definitive scientific research indicating that taking Cosentyx (secukinumab) directly impacts the efficacy of vaccines [1]. However, it is important to note that Cosentyx is a biologic medication used to treat various autoimmune conditions, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. Biologic medications like Cosentyx work by targeting specific proteins in the immune system, which may affect the body's overall immune response [3].
The impact of biologic medications on vaccine efficacy can be complex. Some studies suggest that certain biologic drugs might affect the immune response to vaccines, particularly live vaccines [4][5]. However, these studies do not specifically mention Cosentyx or secukinumab.
Patients taking Cosentyx or other biologic medications should consult their healthcare providers before receiving any vaccinations [1]. Healthcare providers will consider the patient's medical history, the type of vaccine, and the specific biologic medication when determining the best course of action [4].
In summary, there is no direct evidence that Cosentyx use impacts the efficacy of vaccines. However, patients taking biologic medications like Cosentyx should consult their healthcare providers before receiving vaccinations due to the potential complex interactions between biologics and the immune system.
Sources:
[1] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) - DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/drugs/cosentyx
[2] Novartis. (2021). Cosentyx (secukinumab). Retrieved from https://www.cosentyx.com/
[3] Mayo Clinic. (2020). Biologic therapies. Retrieved from https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/in-depth/biologic-therapies/art-20046751
[4] Centers for Disease Control and Prevention. (2019). General best practice guidelines for immunization: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Retrieved from https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
[5] Wolfe, M. S., & Michaud, K. (2015). Biologic therapy for rheumatoid arthritis: What is the risk of serious infection? Therapeutic Advances in Musculoskeletal Disease, 7(6), 223-233. doi:10.1177/1759720x15592322